Asian Low-Carbohydrate Diet with Increased Whole Egg Consumption Improves Metabolic Outcomes in Metabolic Syndrome: A 52-Week Intervention Study.
Study Goal
The researchers aimed to compare the metabolic effects of an Asian ketogenic diet (AKD) with a balanced low-caloric diet (BLC) in individuals with metabolic syndrome (MetS), focusing on weight loss, insulin resistance, lipid profiles, and inflammation.
Results Summary
The AKD groups showed significant improvements in weight, waist circumference, insulin resistance, triglyceride levels, and liver function compared to the BLC group. The Yolk-AKD group also exhibited reduced inflammation-related hormones, while both AKD variants maintained benefits over 52 weeks.
Population
Individuals diagnosed with metabolic syndrome (MetS), with sample sizes of 28 (Yolk-AKD), 26 (White-AKD), and 22 (BLC).
Effective Dosage
Not specified (dietary intervention, not supplement-based).
Duration
52 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Asian ketogenic diet (AKD) | decrease | weight | individuals diagnosed with MetS | - | achieved significant reductions | #1 |
Asian ketogenic diet (AKD) | decrease | waist circumference | individuals diagnosed with MetS | - | achieved significant reductions | #2 |
Asian ketogenic diet (AKD) | decrease | insulin resistance | individuals diagnosed with MetS | - | demonstrated significant improvements | #3 |
Yolk-AKD | decrease | triglyceride concentrations | individuals diagnosed with MetS | - | demonstrated significant improvements | #4 |
White-AKD | decrease | triglyceride concentrations | individuals diagnosed with MetS | - | demonstrated significant improvements | #5 |
Asian ketogenic diet (AKD) | improvement | hormones associated with insulin sensitivity and appetite | individuals diagnosed with MetS | - | experienced improvements | #6 |
Yolk-AKD | decrease | inflammation-related hormones | individuals diagnosed with MetS | - | had a significant decrease | #7 |
Asian ketogenic diet (AKD) | decrease | anthropometric measurements | individuals diagnosed with MetS | - | maintained reductions | #8 |
Asian ketogenic diet (AKD) | decrease | blood pressure | individuals diagnosed with MetS | - | maintained reductions | #9 |
Asian ketogenic diet (AKD) | improvement | glucose tolerance | individuals diagnosed with MetS | - | improved | #10 |
Asian ketogenic diet (AKD) | improvement | lipid profiles | individuals diagnosed with MetS | - | enhanced | #11 |
Asian ketogenic diet (AKD) | improvement | liver function | individuals diagnosed with MetS | - | better | #12 |
BACKGROUND: The low-carbohydrate-ketogenic diet, an effective strategy to address metabolic syndrome (MetS) and obesity has raised concerns about high-fat consumption on atherogenic lipoproteins. OBJECTIVE: The aim of this study was to compare the Asian ketogenic diet (AKD), which incorporates balanced protein and fat intake from Asian foods, with a balanced low-caloric diet (BLC) in individuals diagnosed with MetS. METHODS: A 52-wk randomized clinical trial included 3 parallel groups: AKD with increased whole egg intake [egg yolk Asian ketogenic diet (Yolk-AKD, n = 28)], yolk-free ketogenic diet with egg white supplementation [egg white Asian ketogenic diet (White-AKD, n = 26)], and BLC (n = 22). Primary outcomes were anthropometric and metabolic changes. RESULTS: The AKD groups achieved significant reductions in weight and waist circumference (P < 0.05). Compared with the BLC group, the AKD groups demonstrated significant improvements in insulin resistance at week 6 and in triglyceride concentrations at weeks 12 (Yolk-AKD) and 35 (White-AKD) (P < 0.05). The AKD groups experienced improvements in hormones associated with insulin sensitivity and appetite, whereas only the Yolk-AKD group had a significant decrease in inflammation-related hormones (P < 0.05). From weeks 35-52, the AKD maintained reductions in anthropometric measurements, blood pressure, improved glucose tolerance, enhanced lipid profiles, and better liver function compared with the BLC. CONCLUSIONS: The AKD proved safe and effective, yielding various metabolic improvements in individuals with MetS compared with the BLC. Emphasizing a low-saturated fat diet while disregarding dietary cholesterol, this approach holds promise for MetS and obesity management. The inclusion of both White-AKD and Yolk-AKD groups allowed for a comprehensive assessment of the AKD's impact, elucidating the differential effects of whole egg consumption on metabolic outcomes. Further studies are warranted. This trial was registered at clinicaltrials.gov as NCT04608136.